Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OABI
OABI logo

OABI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.510
1 Day change
-4.43%
52 Week Range
2.470
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

OmniAb Inc (OABI) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak financial performance, negative technical indicators, and lacks any significant positive catalysts or trading signals. It is better to wait for improved fundamentals or stronger trading signals before considering an investment.

Technical Analysis

The stock is in a bearish trend with the MACD histogram at -0.0307 and negatively expanding, indicating downward momentum. The RSI is at 18.532, signaling an oversold condition. The stock is trading near its support level of 1.608, with resistance levels at 1.74 and 1.873. Moving averages are converging, showing no clear direction.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
5

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

  • Weak financial performance in Q3 2025, with revenue dropping by 46.33% YoY, EPS down 12.50% YoY, and gross margin significantly negative at -45.47%. Technical indicators suggest bearish momentum. Stock trend analysis predicts further declines in the short and medium term.

Financial Performance

In Q3 2025, revenue dropped by 46.33% YoY to $2,239,000. Net income slightly improved YoY but remains negative at -$16,525,000. EPS declined to -0.14, down 12.50% YoY. Gross margin is significantly negative at -45.47%, indicating poor operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for this stock.

Wall Street analysts forecast OABI stock price to rise
6 Analyst Rating
Wall Street analysts forecast OABI stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.510
sliders
Low
3
Averages
6.8
High
11
Current: 1.510
sliders
Low
3
Averages
6.8
High
11
Craig-Hallum
Buy
downgrade
$10 -> $7
AI Analysis
2025-11-05
Reason
Craig-Hallum
Price Target
$10 -> $7
AI Analysis
2025-11-05
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.

People Also Watch